Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/02/2020 07/06/2020 07/07/2020 07/08/2020 07/09/2020 Date
76.35(c) 76.76(c) 76.42(c) 75.61(c) 74.71(c) Last
6 380 965 7 056 597 5 055 744 6 293 450 5 199 791 Volume
+0.38% +0.54% -0.44% -1.06% -1.19% Change
More quotes
Financials (USD)
Sales 2020 22 942 M - -
Net income 2020 4 183 M - -
Net cash position 2020 1 769 M - -
P/E ratio 2020 23,3x
Yield 2020 3,57%
Sales 2021 23 234 M - -
Net income 2021 6 683 M - -
Net cash position 2021 4 595 M - -
P/E ratio 2021 14,6x
Yield 2021 3,71%
Capitalization 94 843 M 94 843 M -
EV / Sales 2020 4,06x
EV / Sales 2021 3,88x
Nbr of Employees 11 800
Free-Float 99,4%
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.5%): especially royalties and... 
More about the company
Surperformance© ratings of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES, INC.
02:02aGILEAD SCIENCES : to deliver more remdesivir to Europe from autumn - WiWo
RE
07/08GILEAD SCIENCES : Statement on the Initiation of Clinical Testing of an Inhaled ..
PU
07/08EXCLUSIVE : EU secures potential COVID-19 drugs from Roche, Germany's Merck
RE
07/08EXCLUSIVE : EU secures potential COVID-19 drugs from Roche, Germany's Merck - so..
RE
07/08GILEAD SCIENCES : Presents Survey Findings on PrEP Access and Utilization in the..
BU
07/07GSK to develop plant-based COVID-19 vaccine with Canada's Medicago
RE
07/06Precision BioSciences Says Gilead Ends Hepatitis B Collaboration
DJ
07/06GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
AQ
07/06GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
AQ
07/06GILEAD SCIENCES : New Findings on Gilead's Biktarvy Presented at AIDS 2020, Virt..
AQ
07/06GILEAD SCIENCES : European Commission Grants Conditional Marketing Authorization..
AQ
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
07/05Correction to Poor Performance of Health-Care Stocks Article
DJ
07/05Coronavirus Is No Cure for Health-Care Stocks
DJ
07/04GILEAD SCIENCES : Presents Data Supporting a Potential Six-Month Dosing Interval..
BU
More news
News in other languages on GILEAD SCIENCES, INC.
08:35aWALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
02:02aGILEAD SCIENCES : to deliver more remdesivir to Europe from autumn - WiWo
07/08GILEAD SCIENCES : Statement on the Initiation of Clinical Testing of an Inhaled ..
07/08EXCLUSIVE : EU secures potential COVID-19 drugs from Roche, Germany's Merck
07/08EXCLUSIVE : EU secures potential COVID-19 drugs from Roche, Germany's Merck - so..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Stock Trading Strategies
GILEAD SCIENCES - 02/03
Volatility should make a big comeback
BUY
More Stock Trading Analysis
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 80,56 $
Last Close Price 75,61 $
Spread / Highest target 28,3%
Spread / Average Target 6,55%
Spread / Lowest Target -23,3%
EPS Revisions
Managers
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.16.36%94 843
VERTEX PHARMACEUTICALS35.15%76 725
REGENERON PHARMACEUTICALS70.54%65 029
WUXI APPTEC CO., LTD.47.29%31 931
GENMAB A/S55.25%22 843
BEIGENE, LTD.23.13%15 937